The Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.

The high cost of insulin to treat diabetes would be drastically reduced under legislation the U.S. House of Representatives passed on March 31, in a rare example of drug price reform gaining traction in Congress.

Novo Nordisk more than doubled the Danish drugmaker’s target for sales of obesity medicines by 2025 after overwhelming demand for the company’s new Wegovy product.

Novo Nordisk on Feb. 2 rejected allegations by a U.S. congressional investigative committee that the company has engaged in maneuvers to increase net prices on life-saving insulin in tandem with its competitors on the U.S. insulin market.

Building on Novo Nordisk’s success during June 2021 in obtaining the first drug approval for weight management since 2014, the Danish pharma giant is partnering with biotech company EraCal Therapeutics to develop new obesity-related drug targets. 

Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on December 10 by the House Oversight Committee that highlighted Lilly, Novo Nordisk and Sanofi, which control the market for insulin.

Shares of Dicerna Pharmaceuticals exploded today after Novo Nordisk announced plans to acquire the Lexington, Mass.-based , a company developing RNAi therapeutics, company for $3.3 billion.

The Novo Nordisk Foundation is partnering with the Broad Institute of MIT and Harvard University to launch a massive genetic data mining project that aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.

The pandemic is pushing more people to seek treatment for obesity, Novo Nordisk’s top boss said on Aug. 5, referring to strong sales of the newly launched drug Wegovy, which helped the drugmaker raise its earnings forecast for full-year 2021.

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp.’s experimental heart therapy PRX004 in a deal that could be worth up to $1.23 billion, the companies said on July 12.